Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016146 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00016146: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00016146 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016146, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with biological therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness in combining vaccine therapy and biological therapy in treating patients who have relapsed prostate cancer.
Interventions
- BIOLOGICAL MUC-2-Globo H-KLH conjugate vaccine
- BIOLOGICAL GPI-0100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2000-07 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016146
The ClinicalTrials.gov registry entry for NCT00016146 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MUC-2-Globo H-KLH conjugate vaccine is the first listed.
NCT00016146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016146 about?
NCT00016146 is a clinical study titled "Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining vaccine therapy with biological therapy may kill more tumor cells. PURPOSE: Phase I trial to study...
What is the current status of trial NCT00016146?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2000-07. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00016146?
The interventions under investigation include: MUC-2-Globo H-KLH conjugate vaccine (BIOLOGICAL), GPI-0100 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00016146?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.